Bob Baker, formerly of Glebar Company and Stryker Corporation is the new Chief Executive Officer and board member at Totowa, New Jersey-based Medin Technologies, Inc.
Bob Baker New CEO at Medin Technologies
Medin Technologies is an orthopedic contract manufacturer which designs and manufactures custom sterilization cases and trays for orthopedic medical device companies. Its sister company, Monroe, Washington-based AMT Medical, Inc, is a “contract manufacturer of orthopedic implants and surgical instruments.”
Baker comes to Medin Technologies from Ramsey, New Jersey-based Glebar Company, a machine manufacturer for the medical device industry and other industries. Prior to his role as Glebar Company CEO, Baker spent 12 years with Kalamazoo, Michigan-based Stryker Corporation. At Stryker, Baker held positions of increasing responsibility, with his last role as vice president of global operations supporting Stryker’s orthopedics group.
Prior to joining Stryker, Baker served as a captain in the United States Army and served in both Iraq and Afghanistan.
OTW spoke with Baker about his new role saying, “This is an exciting time for the orthopedic industry, and I look forward to unifying Medin and AMT under a single brand that will allow us to accelerate innovation and customer value.”
“Customer relationships are my first priority, and I look forward to engaging with new and existing clients from our global markets as we listen to their challenges and address how we are accelerating operations to meet pent up demand in a post-COVID environment.”
Baker continued, “Corporate culture is essential. I will be collaborating with our leadership team to unify these brands under one organization that is focused on delivering the very best experience for customers and employees alike.”
Baker added, “Innovation is key to our long-term, continued success. I will be engaging with teams from Medin and AMT to leverage best practices that will deliver new and improved offerings and services to our customers.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.